4.93
0.07 (1.44%)
| Penutupan Terdahulu | 4.86 |
| Buka | 4.83 |
| Jumlah Dagangan | 1,201,139 |
| Purata Dagangan (3B) | 1,827,214 |
| Modal Pasaran | 688,541,888 |
| Harga / Jualan (P/S) | 64.26 |
| Harga / Buku (P/B) | 4.21 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Aug 2026 |
| Margin Operasi (TTM) | -1,222.27% |
| EPS Cair (TTM) | -1.59 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -39.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.72% |
| Nisbah Semasa (MRQ) | 5.06 |
| Aliran Tunai Operasi (OCF TTM) | -12.32 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -52.41 M |
| Pulangan Atas Aset (ROA TTM) | -18.20% |
| Pulangan Atas Ekuiti (ROE TTM) | -91.03% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Aclaris Therapeutics, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | -0.13 |
|
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 2.69% |
| % Dimiliki oleh Institusi | 88.24% |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| GOWEN MAXINE | - | - | 0 | 0 |
| HUMPHRIES WILLIAM D. | - | - | 0 | 0 |
| MEHRA ANAND | - | - | 0 | 0 |
| MILANO VINCENT | - | - | 0 | 0 |
| MOLINEAUX CHRISTOPHER P. | - | - | 0 | 0 |
| SCHIFF ANDREW N | - | - | 0 | 0 |
| Jumlah Keseluruhan Kuantiti Bersih | 0 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 0 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| GOWEN MAXINE | Pengarah | 05 Jun 2026 | Pelaksanaan pilihan | 11,580 | - | - |
| MEHRA ANAND | Pengarah | 05 Jun 2026 | Pelaksanaan pilihan | 11,580 | - | - |
| HUMPHRIES WILLIAM D. | Pengarah | 05 Jun 2026 | Pelaksanaan pilihan | 11,580 | - | - |
| SCHIFF ANDREW N | Pengarah | 05 Jun 2026 | Pelaksanaan pilihan | 11,580 | - | - |
| MILANO VINCENT | Pengarah | 05 Jun 2026 | Pelaksanaan pilihan | 11,580 | - | - |
| MOLINEAUX CHRISTOPHER P. | Pengarah | 05 Jun 2026 | Pelaksanaan pilihan | 11,580 | - | - |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |